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Background: To assess the accuracy of ultrasound-guided 16G or 18G core needle biopsy (CNB) for ultrasound-visible
breast lesions, and to analyze the effects of lesion features.
Methods: Between July 2005 and July 2012, 4,453 ultrasound-detected breast lesions underwent ultrasound-guided
CNB and were retrospectively reviewed. Surgical excision was performed for 955 lesions (566 with 16G CNB and 389 with
18G CNB) which constitute the basis of the study. Histological findings were compared between the ultrasound-guided
CNB and the surgical excision to determine sensitivity, false-negative rate, agreement rate, and underestimation rate,
according to different lesion features.
Results: Final pathological results were malignant in 84.1% (invasive carcinoma, ductal carcinoma in situ, lymphoma,
and metastases), high-risk in 8.4% (atypical lesions, papillary lesions, and phyllodes tumors), and benign in 7.5%.
False-negative rates were 1.4% for 16G and 18G CNB. Agreement rates between histological findings of CNB and
surgery were 92.4% for 16G and 92.8% for 18G CNB. Overall underestimate rates (high-risk CNB becoming malignant
on surgery and ductal carcinoma in situ becoming invasive carcinoma) were 47.4% for 16G and 48.9% for 18G CNB.
Agreements were better for mass lesions (16G: 92.7%; 18G: 93.7%) than for non-mass lesions (16G, 85.7%; 18G, 78.3%)
(P <0.01). For mass lesions with a diameter ≤10 mm, the agreement rates (16G, 83.3%; 18G, 86.7%) were lower (P <0.01).
Conclusions: Ultrasound-guided 16G and 18G CNB are accurate for evaluating ultrasound-visible breast mass lesions
with a diameter >10 mm.
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Percutaneous ultrasound- and stereotactic-guided breast
core needle biopsy (CNB) is widely used as a reliable
alternative to surgical biopsy to obtain a histological
diagnosis for imagery-visible suspicious breast lesions
[1-3]. Stereotactic-guided percutaneous breast biopsy is
mostly used for micro-calcifications, while ultrasound-guided
biopsy is mostly used for masses and architectural
distortions. Previous studies showed that stereotactic-guided
CNB using a large needle gauge provided an accurate
diagnosis [4,5].
However, the accuracy of using 16G and 18G needles for
ultrasound-guided CNB, especially for ultrasound-visible
mass lesions, have not been fully assessed. Few distinctions
are made between stereotactic and ultrasound-guidance* Correspondence: txiner@vip.sina.com
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reproduction in any medium, provided the orCNB when needle size is discussed [6]. Little informa-
tion is currently available about needle size selection
for ultrasound-guided biopsies of lesions with different
imagery features, and most of this information comes
from non-breast lesions [7], or from studies that used 14G
needles only [8-18]. Therefore, one may raise the question
about whether ultrasound-guided CNB with smaller
needles, such as 16G and 18G, can have diagnostic
value for ultrasound-visible lesions, and if there is any
difference in the accuracy of biopsies of breast lesions
with different imaging features.
In this article, we present a large series of breast
lesions that underwent ultrasound-guided 16G or 18G
CNB followed by subsequent surgical excision. We
hypothesized that smaller gauge CNB provides results that
are usable in a routine clinical setting. The objectives were
to assess the accuracy of this technique for ultrasound-
visible breast lesions, and to analyze the effects of lesiontd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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needles that are less expensive and less traumatic for the
patient, without impairing the accuracy of the biopsy.
Methods
Patients
From July 2005 to July 2012, 4,453 consecutive ultrasound-
detected breast lesions were biopsied in our department.
Out of these 4,453 biopsies, 2,646 were performed using
16G CNB, and 1,807 were performed using 18G CNB.
Inclusion criteria were: i) ultrasound-visible breast lesion; ii)
16G or 18G CNB; iii) subsequent surgery to remove the
lesion; and iv) a complete dataset. Exclusion criteria were: i)
previous surgery of the target lesion; ii) stereotactic biopsy;
or iii) any intervention performed on the target lesion
before ultrasound-guided CNB. A total of 934 patients
(928 women, 6 men) with 955 breast lesions were therefore
included in the present study.
This study was approved by the ethical committee of
our hospital and complied with the Health Insurance
Portability and Account Ability Act. According to our
hospital guidelines, informed consent for biopsy and use
of related data for future study was obtained from each
patient before the examination.
Lesions
Breast Imaging Reporting and Data System (BI-RADS)
categories are routinely used for reporting lesions at our
department. Lesions categorized as BI-RADS 4 or 5 usually
undergo biopsy. Lesions categorized as BI-RADS 3 may
also undergo biopsy if the lesions are evolving during
follow-up or according to patients’ and/or surgeons’ will.
All lesions were: i) ultrasound-visible solid lesions; ii)
lesions with a solid component on ultrasound; or 3)
non-mass lesions visible on ultrasound. An ultrasound-
visible “mass lesion” is a space-occupying lesion, while a
“non-mass lesion” is visible as an irregular hypoechoic area
with an indistinct margin on multiple different ultrasound
images (heterogeneous hypoechoic area, ill-defined lobulated
mass, or an enlarged duct) [19].
Biopsy procedure
At our department, an ultrasound-guided biopsy is
initially performed on ultrasound-visible breast lesions
regardless of their palpability; 16G and 18G CNB are
routinely used and the choice is predominantly determined
by the radiologist’s preference. When patients have
poor blood dyscrasia or are under anticoagulant therapy,
an 18G CNB is strongly recommended. All biopsies were
performed by a team of 9 radiologists with either fel-
lowship training or an extensive clinical image and
interventional experience of at least 5 years in breast
imaging and biopsy.Ultrasound examinations were performed using a
Sequoia 512 scanner (Siemens-Acuson, Mountain View,
CA, USA) equipped with a 15L8w linear-array transducer,
and an iU22 scanner (Philips Ultrasound, Bothell,
WA, USA) with a L12-5 linear-array transducer. Biopsies
were performed with a 16G or 18G core needle (CR Bard,
Covington, GA, USA) with 15- or 22-mm throw. The
choice of needle excursion (short throw: 15 mm or long
throw: 22 mm) was based on the lesion size, its position,
and the thickness of glandular parenchyma. For lesions
smaller than 15 mm or near the pectoralis major muscle
or if the patient’s glandular parenchyma was very thin, the
short throw device was used; on the contrary, for lesions
larger than 15 mm or without special location, the long
throw device was routinely used.
Two or three core samples were obtained in most
of the lesions, while two to six core samples were
harvested when the lesion had indistinct margins,
such as non-mass lesions. The appearance and behavior of
the formalin-fixed core samples were examined during
the procedure to confirm that the targeted lesion was
adequately sampled.
Post-fire needle position verification was routinely
performed in all biopsies. The punctures were compressed
for 5–10 min to control bleeding.
Post-biopsy management
CNB pathological examinations were performed by a
dedicated breast pathologist, and the results were
categorized as malignant, high-risk, or benign. Malignant
results included invasive carcinoma, ductal carcinoma in
situ (DCIS), lymphoma, and metastases. High-risk results
included atypical ductal hyperplasia (ADH), atypical lobu-
lar hyperplasia (ALH), lobular carcinoma in situ (LCIS),
papillary lesions (intra-ductal papilloma and papilloma
with atypia), and phyllodes tumors. All other lesions were
categorized as benign findings [16]. Occasionally, when
the findings were unclear, a group of pathologists
examined the specimens and the final histopathological
results were documented as the highest risk lesion.
The radio-pathological concordance was performed
between CNB results and imaging findings for each
case. If the CNB yielded malignant lesions, the patient
underwent the respective surgery. In high-risk cases
on CNB, indeterminate cases, or radio-pathological
discordance, surgical excision was performed. If the
CNB yielded benign results concordant with imaging,
long-term follow-up was recommended. However, some
concordant benign lesions underwent surgical excision at
the patient’s request.
Data analysis
The diagnostic accuracy of ultrasound-guided CNB was
assessed based on the gold standard of the histopathological
Table 1 Characteristics of ultrasound-guided 16G/18G









<40 166 102 64
40–50 382 234 148
50–60 235 133 102
60–70 119 62 57
≥70 53 35 18
BI-RADS# 0.459
3 70 42 28
4 568 345 223
5 317 179 138
Lesions size (mm) 0.065
≤10 133 72 61
11–20 387 235 152
21–50 404 244 160
>50 31 15 16
Calcifications 0.056
Present 319 176 143
Absent 636 390 246
Lesions type 0.082
Mass 911 545 366
Non-mass 44 21 23
*According to unpaired t-test, χ2 test, or Fisher’s exact test, as appropriate.
BI-RADS: breast imaging reporting and data analysis.
#3: Probably benign lesions; 4: Suspicious of malignancy (possibility 3%–94%);
5: Highly suggestive of malignancy (>95%).
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rates, agreement rates, high-risk underestimation rates,
and DCIS underestimation rates were calculated for
ultrasound-guided CNB.
The high-risk underestimation rate was defined as the
proportion of lesions diagnosed as high-risk by CNB that
were upgraded to malignancy after surgical excision. The
DCIS underestimation rate was defined as the proportion
of lesions diagnosed as DCIS by CNB but upgraded to
invasive cancer after surgical excision. The false-negative
rate was defined as the proportion of all breast cancers at
surgery with a benign diagnosis on CNB. The complete
sensitivity was defined as the false-negative rate subtracted
from one. The absolute sensitivity rate was defined as
the proportion of malignancies that were identified by
ultrasound-guided CNB. The agreement rate was defined
as the proportion of lesions that were not classified
as DCIS underestimation, high-risk underestimation,
or false-negative diagnosis. For clinically-relevant purposes,
a lesion with a benign diagnosis on CNB which was then
upgraded to high-risk after excision, was reclassified
as being in agreement because no clinical consequences
would result [20].
For the false-negative rates, sensitivities, underestimation
rates, and agreement rates of the ultrasound-guided CNB,
the type of imagery lesion (mass or non-mass), lesion
size (≤5, 6–10, 11–20, 21–50, and >50 mm), needle
gauge (16G or 18G), and calcifications (with or without)
were assessed.
All analyses were performed using SPSS 18.0, standard
version (SPSS Inc., Chicago, IL, USA). Continuous variables
were expressed as mean ± SD. Student’s t-test was
used to analyze continuous variables. The χ2 test, Fisher’s
exact test, or Kruskal-Wallis test were used for univariate
comparisons. P values <0.01 were considered statistically
significant.Results
Patients’ mean age was 48.9 ± 11.4 years (range: 15–85)
for 16G CNB and 49.8 ± 11.3 years (range: 16–87) for
18G CNB. Among all lesions, 885 lesions were BI-RADS
4 or 5, and 70 were BI-RADS 3. The mean lesion size
was 22 ± 12 mm (range: 3–100) in the 16G group and
23 ± 13 mm (range: 4–83) in the 18G group. The mean
number of cores for 16G and 18G CNB were 2.8 ± 0.5
(range: 2–6) and 2.8 ± 0.5 (range 2–6), respectively. There
were no differences in the breast lesion characteristics
between the two gauges (Table 1).
Pathological examination of the CNB revealed that
malignant lesions accounted for 84.1% (n = 803) of
CNB, high-risk lesions accounted for 8.4% (n = 80),
and benign lesions accounted for 7.5% (n = 72)
(Table 2).False-negative rates, sensitivities, underestimation rates,
and agreement rates of 16G and 18G CNB compared with
the final surgical histological results were calculated ac-
cording to the CNB gauge, lesion type, lesion size, and cal-
cifications (Table 3). False-negative rates were 1.4% for
16G and 18G CNB. Agreement rates between histological
findings of CNB and surgery were 92.4% for 16G and
92.8% for 18G CNB, and there was no difference between
the two gauges (P >0.01). However, there was a risk of
underestimation with 16G and 18G CNB. The high-risk
underestimation rates were 24/50 (48.0%) for 16G CNB
and 16/30 (53.3%) for 18G CNB. The DCIS underestima-
tion rates were 12/26 (46.2%) for 16G CNB and 7/17
(41.2%) for 18G CNB. There were no statistical differences
between the two gauges.
For both 16G and 18G CNB, the absolute sensitivities
and agreement rates were better for mass lesions than
for non-mass lesions, reaching statistical significance in
18G CNB (absolute sensitivity: mass: 94.2% vs. non-mass:
89.5%; agreement: mass: 93.7% vs. non-mass: 78.3%; all
P <0.01). Results showed a significant trend toward a
better agreement of CNB with increasing mass size.
Table 2 Histopathological findings of breast
ultrasound -guided CNB
Pathology findings (n = 955) 16G (n) 18G (n)
Benign 39 33
Breast normal tissue 3 1
Fibroadenoma 9 9






Papillary lesion 18 6
Atypical papillary lesion 4 5
Phyllodes 5 1
Radial scar 2 1





Mucinous Ca 10 11
Papillary Ca 4 3
Tubular Ca 2 1
Medullary Ca 3 0
Lymphoma 1 1
Minimal invasion 1 0
Invasive carcinoma not specified 18 7
Total 566 389
ADH: Atypical ductal hyperplasia; ALH: Atypical lobular hyperplasia; DCIS:
Ductal carcinoma in situ; IDC: Invasive ductal carcinoma; ILC: Invasive lobular
carcinoma; LCIS: Lobular carcinoma in situ; Ca: Carcinoma.
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and agreement rates were the lowest when mass size
was ≤10 mm (accounting for 13.9% of CNB in the
present study). In addition, although lesions with calcifica-
tion had higher agreement rates (18G: 94.4 vs. 91.9%; 16G:
95.5 vs. 91.0%) and lower underestimation rates
(18G: 40.0 vs. 53.0%; 16G: 33.3 vs. 51.7%) than lesions
without calcification (Table 3), there were no significant
differences between the two groups.
Discussion
Minimally invasive percutaneous CNB is used for
ultrasound-visible breast lesions, but no study has previously
assessed the accuracy of CNB using 16G or 18G needles.
The objective was then to assess the accuracy of this
technique for ultrasound-visible breast lesions, and to
analyze the effects of lesions’ image features. Results
showed that false-negative rates were low for 16G and
18G CNB, and that agreement rates between histologicalfindings of CNB and surgery were >92% for 16G and 18G
CNB. Agreements were better for mass lesions than for
non-mass lesions. Agreement rates were lower for mass
lesions with a size ≤10 mm.
Ultrasound-guided CNB has become the first biopsy
choice for ultrasound-visible lesions [21]. It offers several
advantages over stereotactic guidance, including no
radiation, full real-time control of the needle position,
and patients’ comfort without breast compression. It
is also more flexible for biopsy of multiple lesions or in
difficult places (such as the axilla or near the nipple) [22].
Previous studies showed that ultrasound-guided CNB had a
high accuracy when using 14G needles [2,10,13,16,20-22].
However, very little information is currently available
about how these results may vary when the biopsies
are performed using smaller size needles, and most of
these results are from non-breast studies [7].
China has different ethnic populations and different
medical treatment situations compared with most Western
countries. In addition, Asian women are observed to have
smaller breasts and denser mammary parenchyma than
Caucasian women [23]. Due to the magnitude of breast
cancer risk factors, genetic and/or environmental discrep-
ancies, breast cancer in China shows aggressive behaviors.
In patients with a large tumor size (>2–5 cm, accounting
for 51.3% of cases), the mean age is in the 40s, which is a
decade earlier than what is reported in Western countries
[24,25]. Ultrasound-guided biopsies are more sensitive to
detect breast cancers than stereotactic-guided ones in
young women, especially for invasive carcinoma [26].
Further, the use of ultrasound in a screening setting is
widespread in China. Ultrasound-guided CNB is the first
choice for performing a percutaneous biopsy for most
lesions seen or found to be highly suspicious on ultra-
sound. In China, 16G or 18G core needles are commonly
used in most medical institutes. This is because in regards
to mass lesions, target accuracy and proper procedures are
essential for predicting the final results, regardless of the
size of the core needle or the number of core samples [6].
Moreover, the smaller the needle diameter, the lower the
friction will be with the surrounding tissues. Therefore, the
puncture is easier to make and the strength of the shot is
greater, which is helpful when the breast tissue is dense
and causes difficulties in positioning the needle when the
breast is relatively mobile. In addition, at least in theory,
using small needles should decrease bleeding and pain
[22]. The selection of a small gauge core needle may be
reasonable from the viewpoint of needle handling, and the
samples harvested by ultrasound-guided 16G or 18G CNB
are approved by most pathologists and surgeons in our
hospital. Then, if we assume that tissue samples obtained
by 16G or 18G CNB could be adequate for an accurate
diagnosis, why not use smaller needle for easier biopsy
procedures and fewer complications?
Table 3 Breast CNB accuracy according to gauge, lesion type, lesion size and calcifications
False-negative Underestimation Complete sensitivity Absolute sensitivity Agreement
n (%) n (%) % n (%) n (%)
18G (n = 389)
Mass 4/327 (1.2) 19/38 (50) 98.8 308/327 (94.2) 343/366 (93.7)
Non-mass 1/19 (5.3) 4/9 (44.4) 94.7 17/19 (89.5) 18/23 (78.3)
Mass Size (mm)
≤10 2/47 (4.3) 6/18 (33.3) 95.7 39/47 (83.0) 52/60 (86.7)
11–20 1/134 (0.7) 7/10 (70) 99.3 129/134 (96.3) 141/149 (94.6)
21–50 1/137 (0.7) 6/10 (60) 99.3 131/137 (95.6) 139/146 (95.2)
>50 0/9 (0) 0/0 (0) 100 9/9 (100) 11/11 (100)
Calcifications
Present 2/133 (1.5) 6/15 (40) 98.5 129/133 (97.0) 135/143 (94.4)
Absent 3/213 (1.4) 17/32 (53) 98.6 196/213 (92.0) 226/246 (91.9)
Overall 5/346 (1.4) 23/47 (48.9) 98.6 325/346 (93.9) 361/389 (92.8)
16G (n = 566)
Mass 7/488 (1.4) 33/68 (48.5) 98.6 460/488 (94.3) 505/545 (92.7)
Non-mass 0/17 (0) 3/8 (37.5) 100 14/17 (82.4) 18/21 (85.7)
Mass Size (mm)
≤10 2/58 (3.4) 10/19 (52.6) 96.6 50/58 (86.2) 60/72 (83.3)
11–20 3/208 (1.4) 14/24 (58.3) 98.6 198/208 (95.2) 215/232 (92.7)
21–50 2/213 (0.9) 9/24 (37.5) 99.1 203/213 (95.3) 219/230 (95.2)
>50 0/9 (0) 0/1 (0) 100 9/9 (100) 11/11 (100)
Calcifications
Present 2/166 (1.2) 6/18 (33.3) 98.8 162/166 (97.6) 168/176 (95.5)
Absent 5/339 (1.5) 30/58 (51.7) 98.5 312/339 (92.0) 355/390 (91.0)
Overall 7/505 (1.4) 36/76 (47.4) 98.6 474/505 (93.9) 523/566 (92.4)
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overall false-negative rates of 1.4%, which is acceptable
compared with previously reported rates of 0% to 12%
[13,16,20]. These results confirmed that ultrasound-
guided 16G and 18G CNB are accurate and reliable
alternatives to surgical biopsy for ultrasound-visible
breast lesions.Table 4 Published series of ultrasound-guided CNB
Author Year Core needle size
Parker et al. [32] 1993 14G
Smith et al. [10] 2001 14G
Schoonjans et al. [11] 2001 14G
Memarsadhegi et al. [12] 2003 14G
Cystal et al. [13] 2005 14G
Sauer et al. [14] 2005 14G
Dillon et al. [33] 2005 14G
Schueller et al. [16] 2008 14G
Youk et al. [17] 2010 14G
Povoski et al. [18] 2011 14G
Present study 16G/18GHowever, a significant problem with CNB is the high
rate of histological underestimation. A meta-analysis of
underestimation of high-risk lesions in stereotactic-
guided biopsy showed a rate of 40% [27]. Studies
demonstrated that among lesions yielding DCIS at
ultrasound-guided CNB, surgeries revealed infiltrating
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was even more highly variable (0% to 100%, mean 53%)
[28,29]. Similar to these previous studies, the high-risk
underestimation and DCIS underestimation rates of 16G
and 18G CNB were also relatively high in the present
study. Therefore, we recommend vacuum-assisted
CNB or complete surgical excision of all such lesions
detected by CNB, to ensure the detection of any
coexisting malignancy or invasive cancer.
With the improvement of ultrasound resolution and
contrast, microcalcifications contrasting with background
hypoechoic areas or duct-like structures can now be
detected by ultrasound [30]. It is very important to classify
non-mass lesions visible using ultrasound because these
lesions are more histologically heterogeneous than mass
lesions, and usually include more DCIS and non-palpable
lesions [6]. In the present study, there was a significant
difference in the agreement between mass and non-mass
lesions for 18G CNB. This indicates that for smaller caliber
CNB performed on non-mass lesions, especially 18G, the
diagnosis value is lower than biopsies using a larger core
needle or vacuum-assisted CNB [31].
Small tumor size is proven to contribute to the
inaccuracy of CNB [8]. In our study, the agreements
decreased with smaller lesions. This finding is similar to a
previous study performed using 14G CNB [8]. This may
be the result of the poor lesion or needle visualization
within the small lesion, influenced by partial volume effect
artifacts towards the periphery of the lesion. Therefore,
radiologists must be aware of these difficulties and
should pay extra attention in lesions ≤10 mm when
performing ultrasound-guided CNB. Larger caliber CNB
or vacuum-assisted CNB is recommended.
There are certain limitations in the present study. First,
lesions with benign results at CNB without subsequent
surgical excision have been excluded. Therefore, a selection
bias may exist, and it is possible that there were more
false-negative diagnoses in the excluded cases. That is, the
true sensitivity of CNB using 16G or 18G needles is equal
to or lower than that calculated in this study. Maybe this is
the reason why our false-negative rates are relative high
compared with previous results (Table 4). Although the
reports in Table 4 showed there were few missed malignant
cases in the follow-up period (0 to 3 cases) [11-14], further
study to follow patients with a benign CNB result who did
not undergo excisional biopsy is necessary to know the
actual sensitivities. Secondly, not every case was harvested
with the same number of core samples, although a
previous study indicated that two cores are sufficient
to diagnose breast cancer, assuming that no technical
error occurred [15]. Finally, this study did not make
any direct comparison with 14G ultrasound-guided CNB.
However, our data are compatible with data obtained
using 14G CNB in previous studies [8-18].Conclusions
In conclusion, for ultrasound visible breast lesions, 16G
and 18G ultrasound-guided CNB can be used as an
accurate diagnostic alternative to surgical biopsy, at least
in China. For mass lesions visible on ultrasound with a
size >10 mm, 18G and 16G CNB are accurate and
should be the first choice for ultrasound-guided CNB of
these lesions. For mass lesions with a size ≤10 mm or for
non-mass lesions, large caliber CNB or vacuum-assisted
CNB is necessary. Considering the high rate of underesti-
mation of high risk lesions by ultrasound-guided CNB,
large volume vacuum-assisted biopsy or surgical excision is
strongly recommended.
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